Disclosures/Conflict of Interest: All authors state that they have no conflicts of interest.
Original Research Article
Noninterventional Observational Study Using High-Dose Controlled-Release Oxycodone (CR Oxycodone) for Cancer Pain Management in Outpatient Clinics
Article first published online: 6 SEP 2013
Wiley Periodicals, Inc
Volume 14, Issue 12, pages 1866–1872, December 2013
How to Cite
Baek, S. K., Shin, H. W., Choi, Y. J., Zang, D. Y., Cho, D.-Y., Ryoo, H. M., Baek, J. H., Kim, S. Y. and Song, H.-S. (2013), Noninterventional Observational Study Using High-Dose Controlled-Release Oxycodone (CR Oxycodone) for Cancer Pain Management in Outpatient Clinics. Pain Medicine, 14: 1866–1872. doi: 10.1111/pme.12228
Funding: The study was funded by research grants from the Korean Society for Hospice & Palliative care.
- Issue published online: 11 DEC 2013
- Article first published online: 6 SEP 2013
- Korean Society for Hospice & Palliative care
- Pain Management;
- Hospital Outpatient Clinic
Efficacy, safety, and quality of life (QoL) for patients receiving larger doses of controlled-release oxycodone (CR oxycodone) in outpatient clinics are evaluated.
The use of high-dose CR oxycodone and adjuvant drugs for pain management, pain intensity, parameters associated with quality of life, and adverse effects in cancer patients treated with high-dose CR oxycodone (≥80 mg/day) was prospectively observed for 8 weeks. Data from 486 cancer patients receiving high-dose CR oxycodone were collected from 44 hospitals during the period from February 2009 to March 2010.
Three hundred eighteen of the total 486 patients treated with high-dose CR oxycodone were followed up for 8 weeks. Pain intensity significantly improved from a mean numeric rating scale (NRS) 5.49 to NRS 4.33 (P < 0.0001). Dosage of CR oxycodone increased from a mean of 130.0 to a mean of 174.9 (P < 0.0001). QoL including activity, walking, and sleeping significantly improved after 8 weeks. At baseline, 138 complained of adverse effects, of which constipation (30.2%) was the most common followed by dry mouth (8.8%) and dizziness (8.2%). After 8 weeks, 128 patients complained of adverse effects such as constipation (27.0%), nausea (5.7%), dry mouth (5.7%), and dizziness (5.0%). After 8 weeks of high-dose CR oxycodone, adverse effects did not increase.
This study suggests that over an 8-week period, the use of high-dose CR oxycodone for cancer pain management is efficient, safe, and tolerable in outpatient clinics.